Ascentage Pharma Group International（AAPG）のニュースとイベントAAPGAscentage Pharma Group International

Ascentage Pharma Appoints New CBO and CCO

Ascentage Pharma Group announced the appointment of Faical Miyara, PhD, as Chief Business Officer, CBO, responsible for the Company's global business development, and Jim Ziegler as Chief Commercial Officer, CCO, responsible for the commercialization of the Company's products in the United States and other countries outside of China.

Ascentage Pharma Files to Sell American Depositary Shares

Ascentage Pharma files to sell American Depositary Shares, no amount given

Ascentage Pharma Presents 17 Clinical Updates at EHA2026

Ascentage Pharma announced that seventeen clinical updates from its core assets were presented at the 31st Congress of the European Hematology Association, EHA2026. Title: "Efficacy of Olverembatinib in patients with chronic-phase chronic myeloid leukemia." Highlights: This study provided the first evidence that olverembatinib is active in patients with ponatinib- and/or asciminib-resistant CP-CML, including those harboring challenging genotypes such as ASXL1 mutations, highlighting its potential as a treatment option for patients with multi-line TKI-resistant disease. Title: "Updated efficacy and safety of olverembatinib." Highlights: These findings support the potential of olverembatinib to induce durable and deep responses in patients with CP-CML without the T315I mutation whose disease was resistant and/or intolerant to first-line TKI therapy, further supporting its role as a second-line treatment option. Title: "The efficacy and safety of switching to olverembatinib." Highlights: Notably, 78.57% of adverse events related to prior TKI therapy improved after patients switched to olverembatinib. These findings support olverembatinib as a potential standard of care for patients with CML-CP previously treated with at least two TKIs. Title: "Updated results of Polaris-1, a global registrational Phase 3 study." Highlights: These findings suggest that olverembatinib combined with low-intensity chemotherapy may induce rapid, deep, and sustained MRD-negative responses in patients with newly diagnosed Ph+ ALL, while maintaining a favorable safety profile, and provide important evidence supporting its use in the frontline setting. Title: "Safety and preliminary efficacy of olverembatinib." Highlights: These findings support the potential of this chemotherapy-free oral dual-targeted regimen to induce rapid and deep remissions, and may provide a novel treatment option for pediatric patients with R/R Ph+ ALL. Title: "Real-world efficacy and safety of Lisaftoclax."